L-670596

Cat. No.:	HY-108561
CAS No.:	121083-05-4
Molecular Formula:	$C_{22}H_{21}F_2NO_4S$
Molecular Weight:	433.47
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069[1][2].
In Vitro	L-670596 inhibits the aggregation of human platelet rich plasma induced by U-44069[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	L-670596 (0.03mg/kg ; i.v.; single) inhibits arachidonic acid and U-44069 induced bronchoconstriction in the guinea pig[1]. L-670596 (2 mg/kg; i.v.; single) inhibits platelet aggregation to collagen in pigs[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Guinea pig (arachidonic acid and U-44069 induced bronchoconstriction model)[1].
Dosage:	0.03mg/kg
Administration:	Intravenous injection; single.
Result:	Inhibited arachidonic acid and U-44069 induced bronchoconstriction.

REFERENCES

[1]. Ford-Hutchinson AW, et al. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist. Can J Physiol Pharmacol. 1989 Sep;67(9):989-93.

[2]. Nuttall GA, et al. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology. 1991 Jan;74(1):138-45.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA